hapabapa
Roche (OTCQX:RHHBY) subsidiary Genentech announced on Saturday that its experimental breast cancer therapy, giredestrant, as part of a combination regimen, reduced the risk of disease progression or death in up to 62% of patients in a Phase 3 trial when used as a